ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

6,882Medicare Part D Prescriptions Filled, Including Refills

Rank: 79 out of 817

$353K Total Retail Price of All Prescriptions

Rank: 171 out of 817

315 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
40% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 315 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

15% of this provider’s 315 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

2% of this provider’s 5,291 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $89 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
SIMVASTATIN 457 355 1 1
METOPROLOL TARTRATE 273 224 2 5
LEVOTHYROXINE SODIUM 272 259 3 2
HYDROCODONE-ACETAMINOPHEN 271 143 S3 4 7
LISINOPRIL 267 214 5 3
OMEPRAZOLE 252 167 6 4
AMLODIPINE BESYLATE 217 201 7 6
WARFARIN SODIUM 157 138 8 10
AMLODIPINE BESYLATE-BENAZEPRIL 132 115 9 83
METOPROLOL SUCCINATE 131 105 10 26
FUROSEMIDE 105 81 11 8
METFORMIN HCL 102 76 12 13
TRIAMTERENE-HCTZ 101 74 13 98
POTASSIUM CHLORIDE 94 70 14 18
NEXIUM 91 52 15 57
GABAPENTIN 87 34 16 12
ATENOLOL 86 77 17 14
CYCLOBENZAPRINE HCL 77 42 R 18 76
CLOPIDOGREL 70 60 19 27
ALENDRONATE SODIUM 70 51 19 31
PRAVASTATIN SODIUM 66 55 21 19
TRAMADOL HCL 66 60 21 23
GLIPIZIDE 64 61 23 84
FAMOTIDINE 62 34 24 71
CITALOPRAM HBR 60 21 25 16
COUMADIN 59 59 26 398
EVISTA 57 57 27 129
HYDROCHLOROTHIAZIDE 56 54 28 15
DIOVAN HCT 56 50 28 95
GLIMEPIRIDE 56 40 28 88
BENAZEPRIL HCL 53 51 31 273
PLAVIX 52 47 32 44
ATORVASTATIN CALCIUM 52 49 32 9
DIOVAN 51 50 34 28
TAMSULOSIN HCL 51 42 34 11
ZOLPIDEM TARTRATE 51 28 34 30
CRESTOR 50 50 37 56
ADVAIR DISKUS 50 27 37 32
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.